CA3261198A1 - Pharmaceutical Compositions and Treatment Methods for Insomnia - Google Patents

Pharmaceutical Compositions and Treatment Methods for Insomnia

Info

Publication number
CA3261198A1
CA3261198A1 CA3261198A CA3261198A CA3261198A1 CA 3261198 A1 CA3261198 A1 CA 3261198A1 CA 3261198 A CA3261198 A CA 3261198A CA 3261198 A CA3261198 A CA 3261198A CA 3261198 A1 CA3261198 A1 CA 3261198A1
Authority
CA
Canada
Prior art keywords
pharmaceutical composition
alprazolam
ebastine
amount
range
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3261198A
Other languages
English (en)
French (fr)
Inventor
Jianmin Wang
Geping Cui
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Geping Cui
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3261198A1 publication Critical patent/CA3261198A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4515—Non condensed piperidines, e.g. piperocaine having a butyrophenone group in position 1, e.g. haloperidol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA3261198A 2022-07-08 2022-07-08 Pharmaceutical Compositions and Treatment Methods for Insomnia Pending CA3261198A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2022/036579 WO2024010592A1 (en) 2022-07-08 2022-07-08 Pharmaceutical compositions and methods for treating insomnia

Publications (1)

Publication Number Publication Date
CA3261198A1 true CA3261198A1 (en) 2024-01-11

Family

ID=89453886

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3261198A Pending CA3261198A1 (en) 2022-07-08 2022-07-08 Pharmaceutical Compositions and Treatment Methods for Insomnia

Country Status (7)

Country Link
US (1) US20250205218A1 (https=)
EP (1) EP4551220A1 (https=)
JP (1) JP2025522146A (https=)
CN (1) CN119255803A (https=)
AU (1) AU2022468585A1 (https=)
CA (1) CA3261198A1 (https=)
WO (1) WO2024010592A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12370198B2 (en) 2022-07-08 2025-07-29 La Pharmatech Inc Pharmaceutical compositions and methods for treating psychiatric disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10898493B2 (en) * 2019-04-12 2021-01-26 LA PharmaTech Inc. Pharmaceutical compositions and methods for psychiatric symptoms of patients with Alzheimer's disease
WO2021005189A1 (fr) * 2019-07-09 2021-01-14 Universite De Bretagne Occidentale (Ubo) Nouveaux composés inhibiteurs de la pfar

Also Published As

Publication number Publication date
EP4551220A1 (en) 2025-05-14
US20250205218A1 (en) 2025-06-26
WO2024010592A1 (en) 2024-01-11
AU2022468585A1 (en) 2025-02-20
CN119255803A (zh) 2025-01-03
JP2025522146A (ja) 2025-07-10

Similar Documents

Publication Publication Date Title
US11116773B2 (en) Method of treating dementia
KR101801864B1 (ko) 인플루엔자, 감기 및 염증의 치료에서 레보세티리진 및 몬테루카스트의 용도
US12138269B2 (en) Method of treating dementia
CN113924098A (zh) 治疗精神障碍、行为障碍、认知障碍的方法
US20200101067A1 (en) Use of levocetirizine and montelukast in the treatment of anaphylaxis
US20210069209A1 (en) Novel pharmaceutical compositions and methods for menopause related anxiety and depression
CN113939276A (zh) 用于治疗精神障碍、行为障碍、认知障碍的药物组合物和方法
WO2021242297A1 (en) Novel pharmaceutical compositions and methods for menopause related anxiety and depression
KR20150135339A (ko) 레보세티리진 및 몬테루카스트의 외상성 손상의 치료 용도
US20250205218A1 (en) Pharmaceutical compositions and methods for treating insomnia
US11744833B2 (en) Pharmaceutical compositions and methods for treatment of insomnia
EP4478887A1 (en) Novel pharmaceutical compositions and methods for treatment of insomnia
JP2025518975A (ja) 精神疾患の治療のための新規医薬組成物及び方法
CN1327843C (zh) 氟马西尼在用于可卡因依赖治疗药物制备中的应用
US11628174B1 (en) Pharmaceutical compositions and methods for treating insomnia
US10071077B2 (en) Use of enoximone in the treatment of atopic immune-related disorders, in pharmaceutical composition as well as in pharmaceutical preparation
US12370198B2 (en) Pharmaceutical compositions and methods for treating psychiatric disorders
HK40119515A (zh) 用於治疗失眠症的新型药物组合物和方法
JPWO2005063253A1 (ja) アレルギー症状治療用医薬組成物
HK1064036B (en) Kapp-opiate agonists for the treatment of bladder dieseases
HK1064036A1 (en) Kapp-opiate agonists for the treatment of bladder dieseases

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20250103

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20250407

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250407

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250408

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250707

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250707